JPMorgan Chase & Co. Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $350.00

United Therapeutics (NASDAQ:UTHR) had its price objective trimmed by JPMorgan Chase & Co. from $355.00 to $350.00 in a research report report published on Thursday,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on the stock. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th. Bank of America raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price objective for the company in a research note on Monday, April 21st. Finally, HC Wainwright reissued a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $392.00.

United Therapeutics Price Performance

Shares of UTHR stock opened at $294.60 on Thursday. United Therapeutics has a 1 year low of $256.08 and a 1 year high of $417.82. The firm has a fifty day moving average price of $301.96 and a 200-day moving average price of $344.33. The company has a market cap of $13.28 billion, a price-to-earnings ratio of 12.94, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. During the same quarter in the prior year, the business posted $6.17 earnings per share. The business’s quarterly revenue was up 17.2% on a year-over-year basis. Equities research analysts expect that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $300.93, for a total transaction of $3,310,230.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,068,506.33. This represents a 23.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,500 shares of company stock valued at $27,782,280 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics in the fourth quarter worth about $25,000. Dunhill Financial LLC lifted its stake in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 50 shares during the last quarter. Sound Income Strategies LLC bought a new stake in shares of United Therapeutics during the 1st quarter worth approximately $49,000. State of Wyoming purchased a new position in United Therapeutics during the 4th quarter valued at $62,000. Finally, Curat Global LLC purchased a new stake in United Therapeutics in the first quarter worth $63,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.